March 2020
-
Media ReleaseNovartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human ServicesPrinceton - Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of…
-
Media ReleaseSandoz announces new country head for JapanShingo Iwamoto appointed country head for Sandoz in Japan Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this…
-
Media ReleaseNovartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic responseHydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory…
-
Media ReleaseSandoz Resolves Generic Drug Antitrust Investigation in the U.S.Princeton, New Jersey, March 2, 2020 – Sandoz Inc. has reached a resolution with the U.S. Department of Justice (DOJ) Antitrust Division concerning the Department’s more than three-year-long…
January 2020
-
Media ReleaseSandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicinesSuccessful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines Acquired portfolio…
-
Media ReleaseSandoz officially recognized as Global Top Employer 2020Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally People-first policies such as global equal parental leave for 14 weeks and joining the Equal…
-
Media ReleaseNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and…
November 2019
-
Media ReleaseSandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatmentInterim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
-
Media ReleaseSandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics marketPlanned acquisition reinforces Sandoz strategic focus on Japan Aspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brands Medicines…
-
Media ReleaseSandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only company to offer…